Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:PARNF NASDAQ:PHIO NASDAQ:RTTR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePARNFParnell Pharmaceuticals$0.08$0.08$0.05▼$0.35N/AN/AN/AN/APHIOPhio Pharmaceuticals$1.02-1.9%$1.13$0.81▼$4.19$11.85M0.822.04 million shs414,967 shsRTTRRitter Pharmaceuticals$1.34+8.1%$2.99$0.15▼$1.27$61.85M-0.4314.23 million shs28,860 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePARNFParnell Pharmaceuticals0.00%0.00%0.00%0.00%0.00%PHIOPhio Pharmaceuticals-0.95%-1.89%-4.59%-17.46%-52.29%RTTRRitter Pharmaceuticals0.00%0.00%0.00%+1.52%-62.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePARNFParnell Pharmaceuticals$0.08$0.08$0.05▼$0.35N/AN/AN/AN/APHIOPhio Pharmaceuticals$1.02-1.9%$1.13$0.81▼$4.19$11.85M0.822.04 million shs414,967 shsRTTRRitter Pharmaceuticals$1.34+8.1%$2.99$0.15▼$1.27$61.85M-0.4314.23 million shs28,860 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePARNFParnell Pharmaceuticals0.00%0.00%0.00%0.00%0.00%PHIOPhio Pharmaceuticals-0.95%-1.89%-4.59%-17.46%-52.29%RTTRRitter Pharmaceuticals0.00%0.00%0.00%+1.52%-62.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePARNFParnell Pharmaceuticals 0.00N/AN/AN/APHIOPhio Pharmaceuticals 2.00Hold$14.001,272.55% UpsideRTTRRitter Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PHIO, RTTR, and PARNF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026PHIOPhio Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPARNFParnell PharmaceuticalsN/AN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/A$1.87 per shareN/ARTTRRitter PharmaceuticalsN/AN/AN/AN/A$0.10 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePARNFParnell PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AN/APHIOPhio Pharmaceuticals-$8.70M-$1.38N/AN/AN/AN/A-77.34%-70.87%8/13/2026 (Estimated)RTTRRitter Pharmaceuticals-$10.13MN/AN/AN/AN/AN/AN/A-162.05%N/ALatest PHIO, RTTR, and PARNF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026PHIOPhio Pharmaceuticals-$0.24-$0.34-$0.10-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthPARNFParnell PharmaceuticalsN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ARTTRRitter PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPARNFParnell PharmaceuticalsN/AN/AN/APHIOPhio PharmaceuticalsN/A18.3218.32RTTRRitter PharmaceuticalsN/A3.673.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPARNFParnell PharmaceuticalsN/APHIOPhio Pharmaceuticals57.31%RTTRRitter Pharmaceuticals0.84%Insider OwnershipCompanyInsider OwnershipPARNFParnell PharmaceuticalsN/APHIOPhio Pharmaceuticals0.89%RTTRRitter Pharmaceuticals15.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePARNFParnell Pharmaceuticals51N/AN/ANot OptionablePHIOPhio Pharmaceuticals1011.62 million11.51 millionNot OptionableRTTRRitter Pharmaceuticals746.15 millionN/ANot OptionablePHIO, RTTR, and PARNF HeadlinesRecent News About These CompaniesRochester football bows to St. Louis Cardinal Ritter in battle of state championsOctober 4, 2024 | sj-r.comSScott Ritter claims search of home is related to 'foreign agent’ lawAugust 9, 2024 | timesunion.comTFBI raids NY home of ex-UN weapons inspector Scott RitterAugust 9, 2024 | nypost.comNJohn Ritter Biography & MoviesMay 22, 2024 | tribute.caTJeff RitterApril 19, 2024 | si.comSDr. John D. RitterJanuary 23, 2024 | health.usnews.comGerman chocolate war ends with Ritter Sport victoryOctober 28, 2023 | politico.euPKristen RitterSeptember 15, 2023 | health.usnews.comOp-ed column: Sandusky sex charges contrast with setup against Scott RitterJuly 8, 2023 | dailygazette.comDScott Ritter arrested in Pennsylvania on child sex chargesJuly 8, 2023 | dailygazette.comDDr. Harold K. RitterJuly 8, 2023 | health.usnews.comDenver Business Journal welcomes new tech reporterJuly 1, 2023 | bizjournals.comGary W. Ritter, Ph.D.June 16, 2023 | slu.eduSJason Ritter and Drew Barrymore's raw conversation on her show may matter more than you thinkApril 10, 2023 | usatoday.comRitter Pharmaceuticals Changing the Game With Lactose Intolerance TreatmentMarch 29, 2023 | thestreet.comGlobal Microbiome Market Report 2023: Major Players Include MicroBiome Therapeutics, Seres Therapeutics, Enterome Bioscience and Second GenomeMarch 18, 2023 | finance.yahoo.comMelanie Lynskey's husband Jason Ritter will join her in Yellowjackets this seasonJanuary 19, 2023 | yahoo.comRitter Public Library in Vermilion adds book clubJanuary 15, 2023 | morningjournal.comMMicrobiome Clinical Trial Pipeline Space Brims with Novel Emerging Therapies with 130+ Key Players Working in the Domain | DelveInsightNovember 16, 2022 | finance.yahoo.comBurlington freshman Olivia Ritter hits to pool as Olivia Kraus climbs out of the waterOctober 1, 2022 | thehawkeye.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHIO, RTTR, and PARNF Company DescriptionsParnell Pharmaceuticals OTCMKTS:PARNF$0.08 0.00 (0.00%) As of 06/23/2026Parnell Pharmaceuticals Holdings Ltd, a commercial-stage pharmaceutical company, focuses on developing, manufacturing, and marketing animal pharmaceutical products worldwide. The company operates through four segments: Companion Animal, Production Animal - U.S., Production Animal - Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproductive hormone products for enhancing cattle breeding performance; Zydax for the treatment of osteoarthritis (OA) in dogs and horses; and Glyde, a nutraceutical product for the treatment of OA, as well as Parnell PROcept, which adds an additional injection of estroPLAN after the first injection. The company also offers mySYNCH, a digital tool to help veterinarians and producers optimize reproduction and maximize economic gains. Parnell Pharmaceuticals Holdings Ltd was incorporated in 2009 and is headquartered in Alexandria, Australia.Phio Pharmaceuticals NASDAQ:PHIO$1.02 -0.02 (-1.92%) Closing price 04:00 PM EasternExtended Trading$1.03 +0.01 (+1.08%) As of 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.Ritter Pharmaceuticals NASDAQ:RTTRRitter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why KB Home Could Reward Patient Investors Later Tesla's New NHTSA Probe Lands at the Worst Possible Time Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
